对于神经胃肠病学和运动障碍的数字和传统行为疗法
Pooja N Dave1, Sarah Kinsinger2
1Department of Ambulatory Behavioral Medicine, Wellstar Medical Group, Marietta, GA, USA.
Current gastroenterology reports
|August 4, 2025
概括
大脑肠道行为疗法 (BGBTs) 改善神经胃肠道学和运动障碍. 最近的进展包括数字交付方法,尽管现实世界的有效性需要进一步研究.
科学领域:
- 神经胃肠病学 神经胃肠病学
- 胃肠道运动障碍 胃肠道运动障碍
- 行为心理学 行为心理学
背景情况:
- 大脑肠道行为疗法 (BGBTs) 包括心理和行为干预,如认知行为疗法和肠道导向催眠疗法.
- 这些疗法已被确立为有效的症状管理和提高各种神经胃肠道和运动障碍患者的生活质量.
研究的目的:
- 审查BGBT方法的最新进展.
- 突出旨在增加患者获得护理的新型交付方法.
主要方法:
- 审查关于BGBTs的当前文献.
- 分析不断发展的治疗技术和治疗平台.
主要成果:
- BGBT越来越多地准肠道特异性心理过程,结合暴露技术和正念.
- 包括数字疗法在内的新型传递方法正在扩大获取,但它们的临床可行性和现实世界的有效性仍在调查中.
- BGBT正在应用于更广泛的肠-大脑相互作用障碍 (DGBI).
结论:
- BGBT继续发展,以满足DGBI患者的复杂需求.
- 数字BGBT显示出改善访问的希望,但进一步的研究对于确认其有效性和确定合适的患者群体至关重要.
相关概念视频
Gastrointestinal Motility Disorders
596
Gastrointestinal or GI motility disorders are characterized by irregular gastrointestinal tract movements, disrupting food transit from the mouth to the anus. They are caused by damage or dysfunction in gut muscles or nerves. These disorders can cause symptoms such as severe constipation, diarrhea, abdominal pain, and swallowing difficulties. Disorders can affect any segment of the GI tract and range widely in severity, from common conditions like GERD to life-threatening conditions like...
596
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
617
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
617
Behavior Therapy
110
Behavior therapy incorporates diverse techniques rooted in classical conditioning principles to address maladaptive behaviors and anxiety disorders. These methods aim to reduce avoidance behaviors, foster adaptive coping mechanisms, and alter associations between stimuli and responses, making them effective in a wide range of therapeutic contexts.
Exposure therapy is a cornerstone of behavioral treatment for anxiety disorders. It involves systematic exposure to feared stimuli, either in real...
Exposure therapy is a cornerstone of behavioral treatment for anxiety disorders. It involves systematic exposure to feared stimuli, either in real...
110
Imaging Studies III: Gastrointestinal Motility Studies and Virtual Colonoscopy
142
This lesson explores three gastrointestinal imaging techniques: radionuclide testing, colonic transit studies, and virtual colonoscopy.
Radionuclide Testing
Radionuclide testing is a sophisticated medical technique for assessing gastrointestinal motility. It focuses on gastric emptying and colonic transit time. Radioactive markers track the movement of food through the digestive system, providing insights into gastrointestinal disorders.
In gastric emptying studies, a meal's liquid and...
Radionuclide Testing
Radionuclide testing is a sophisticated medical technique for assessing gastrointestinal motility. It focuses on gastric emptying and colonic transit time. Radioactive markers track the movement of food through the digestive system, providing insights into gastrointestinal disorders.
In gastric emptying studies, a meal's liquid and...
142
Drugs for Treatment of Diarrhea-Predominant IBS
294
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
294
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
402
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
402


